We are live on ! Find out more
CBIO

Crescent Biopharma
CBIO

31 hedge funds and large institutions have $109M invested in Crescent Biopharma in 2015 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 13 increasing their positions, 4 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 1

225% more repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 4

11% more funds holding

Funds holding: 28 → 31 (+3)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

4% less capital invested

Capital invested by funds: $114M → $109M (-$4.93M)

Holders
31
Holders Change
+3
Holders Change %
+10.71%
% of All Funds
0.83%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
4
Increased
13
Reduced
4
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
+$246K
2
Deutsche Bank
Deutsche Bank
Germany
+$219K
3
BCM
Bridgeway Capital Management
Texas
+$185K
4
Renaissance Technologies
Renaissance Technologies
New York
+$141K
5
Fidelity Investments
Fidelity Investments
Massachusetts
+$103K

Top Sellers

Rank Fund Capital Flow
1
JP Morgan Chase
JP Morgan Chase
New York
-$628K
2
SIM
Spark Investment Management
New York
-$130K
3
NFA
Nationwide Fund Advisors
Ohio
-$51.3K
4
Northern Trust
Northern Trust
Illinois
-$16.5K
5
Citigroup
Citigroup
New York
-$12.4K

CBIO Hedge Fund Activity: Q2 2015 in Review

31 of the 3,730 institutional investors tracked by Wall St. Rank reported a position in Crescent Biopharma (CBIO) for Q2 2015, worth a combined $109M — down 4.3% from $114M a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new CBIO positions and 1 closed out — a net gain of 3 holders — while 13 added to existing stakes and 4 trimmed.

The largest buyer was Jacobs Levy Equity Management, opening a new position worth an estimated $246K. The largest seller was JP Morgan Chase, exiting entirely with an estimated $628K sold.

  • 31 institutional investors held Crescent Biopharma (CBIO) as of Q2 2015, up from 28 in Q1 2015.
  • Funds reported $109M of Crescent Biopharma stock for Q2 2015, down 4.3% quarter-over-quarter.
  • 4 funds opened new Crescent Biopharma positions in Q2 2015 and 1 closed out, a net change of +3 holders.
  • The largest Crescent Biopharma buyer in Q2 2015 was Jacobs Levy Equity Management, an estimated $246K added.
  • The largest Crescent Biopharma seller in Q2 2015 was JP Morgan Chase, an estimated $628K sold.

Based on aggregated 13F filings for Q2 2015.